Author: openjargon

The All Ordinaries Index (ASX: XAO) has gained 2.3% over the last year, with this ASX All Ords gold stock leaving those gains wanting.

The high-flying miner in question is New Murchison Gold Ltd (ASX: NMG).

New Murchison shares closed yesterday trading 4.4 cents. In early morning trade on Thursday, shares are changing hands for 43.5 cents apiece, down 1.1%.

Despite today’s dip, that sees the New Murchison Gold share price up an impressive 129% over the past 12 months.

Here’s what’s happening today with the ASX All Ords gold stock.

ASX All Ords gold stock expanding its WA footprint

New Murchison shares look to be under pressure today amid broader weakness in the gold sector.

Overnight, the gold price dipped below US$4,000 per ounce for the first time in 2026. The yellow metal has been in a downtrend over the past month amid rising inflation in Australia, the United States, and most nations.

That’s led to increased expectations of central bank interest rate hikes, particularly the highly influential US Federal Reserve. And gold, which pays no yield itself, tends to perform better in low or declining interest rate environments.

Over the past few hours, the gold price has recovered to US$4,011 per ounce (according to data from Bloomberg). But that hasn’t kept the S&P/ASX All Ordinaries Gold Index (ASX: XGD) from tumbling 3.9% today.

As for New Murchison Gold, in an announcement this morning that should offer longer-term support for the gold miner’s shares, the miner reported on a material Mineral Resource Estimate (MRE) upgrade at its flagship Garden Gully Gold Project, located in Western Australia.

The ASX All Ords gold stock said the new estimates were compiled by independent consultancies, incorporating New Murchison’s updated structural interpretations and latest drilling data at the project.

Management noted, “This global update significantly expands NMG’s production pipeline and underscores the scaling potential of the Garden Gully goldfield.”

Indeed, the project’s MRE reportedly increased by 47%. This expands the total remaining resource to 4.42 million tonnes at 2.5 grams of gold per tonne for 359,000 ounces of contained gold.

The miner highlighted that this represents a 29% increase over the November 2024 MRE estimate. When including full, reconciled production mining up to April 1, 2026, it’s an even more impressive 47% total increase.

“The combined Measured and Indicated categories account for 71% of the global project ounces, ensuring excellent local grade predictability for near-term mine planning,” management said.

Since the 2024 Crown Prince MRE, the ASX All Ords gold stock has followed up on infill and extensional targets and carried out tighter spaced grade control campaigns to increase resource confidence.

The miner noted that the Measured Resource component of 39,000 ounces at 3.83 grams of gold per tonne at the Crown Prince Open Pit deposit, situated within Garden Gully, provides immediate, low-risk mill feed.

The post Up 129% in a year, guess which ASX All Ords gold stock just reported a big resource increase appeared first on The Motley Fool Australia.

More reading

• Up 218% in a year, Mineral Resources shares sinking today amid mine closure news
• Top broker just put a buy rating on this ASX share with 6.7% yield
• A deal with Pro Medicus has turned this ASX biotech into a 10-bagger, up more than 30% today
• Guess which small-cap ASX tech share could rise 60%
• Lendlease offloads Keyton stake in $525m deal

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Lotus Resources Ltd (ASX: LOT) shares have been out of action for a few days now.

And any hopes that they would be coming back soon have been dashed after the uranium developer requested an extension to its voluntary suspension.

The ASX uranium stock now expects to remain suspended until at least 16 July.

Why is this ASX uranium stock suspended?

The company has requested the suspension while it works to secure funding and resolve operational issues at its flagship Kayelekera uranium mine in Malawi.

According to the release, production at Kayelekera has been temporarily paused following disruptions to third-party sulphuric acid supplies and delays commissioning its on-site acid plant.

Lotus Resources said the disruption to acid supply has been linked to ongoing geopolitical tensions in the Middle East, which have affected the availability and cost of sulphur and sulphuric acid.

Compounding the issue, several refractory bricks in the mine’s sulphur furnace failed during commissioning, requiring repairs before the acid plant can resume normal operations.

As a result, steady-state production is now expected later in calendar year 2026, subject to both acid supply and funding.

Funding now a key focus

The company also acknowledged that additional funding is required.

The ASX uranium stock finished the period with a cash balance of US$26 million but said external funding will be necessary to support operations and complete the restart of Kayelekera.

The good news is that Lotus has signed a non-binding term sheet with global commodities trader Mercuria Energy Trading for a marketing agreement and a proposed US$30 million inventory prepayment facility. Binding documentation is now being negotiated.

In addition, the company is pursuing equity and quasi-equity funding options.

However, Lotus warned there is no guarantee any funding arrangements will ultimately be completed.

Production had been improving

Before the latest setbacks, Kayelekera had been showing encouraging signs of improvement.

Production increased from 47,300 pounds of uranium oxide in April to 73,600 pounds in May following operational optimisation initiatives and maintenance improvements.

The company also continues to make progress on export approvals and logistics, with first shipments now expected no earlier than September 2026, subject to remaining permits being secured.

Why the suspension?

The ASX uranium stock said it believes allowing its shares to trade before the funding process is complete could result in the market trading on an uninformed basis and potentially prejudice its ability to finalise financing.

Accordingly, it has asked the ASX to keep its shares suspended until the earlier of announcing a completed funding solution or the resumption of trading on 16 July.

While management maintains that Kayelekera’s long-term investment case remains intact, investors will no doubt want to see the funding package secured and production restart before confidence is fully restored.

The post What’s going on with this ASX uranium stock? appeared first on The Motley Fool Australia.

More reading

• Here are the 10 most shorted ASX shares
• Buy, hold, sell: WiseTech, Lotus Resources, Ampol shares
• Experts name 3 ASX shares to sell this week
• Here are the 10 most shorted ASX shares
• Here are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Northern Star Resources Ltd (ASX: NST) shares have fallen even further into the red in Thursday morning trade.

At the time of writing, the shares are down around 2% and changing hands at $20.22 a piece.

The latest decline means the ASX gold miner’s shares are now around 17% lower for the year-to-date but still roughly 5% above trading levels seen this time last year.

What happened to Northern Star Resources shares this year?

The shares had an incredibly strong start to 2026, climbing almost 30% to an all-time high of $31.73 in early March.

But investors quickly sold their shares in the ASX gold miner shortly after its operational update, causing a 46% share price crash. The shares are now trading around 36% below that peak.

The company also downgraded its FY26 production outlook on two separate occasions earlier this year. At the time, management flagged a weaker-than-expected performance across several key operations.

Gold price weakness also added further pressure. Throughout March, the price of the safe-haven metal crashed from around US$5,300 per ounce to around US$4,300 per ounce. The drop came on the back of inflation concerns and liquidity pressures, which resulted directly from an outbreak of conflict in the Middle East.

The outbreak of the Iran war led investors to sell liquid assets, including gold, to raise cash as broader markets declined. At the same time, rising oil prices increased inflation concerns and raised the prospect of higher interest rates, which is typically negative for gold.

As a gold producer, Northern Star’s revenue is heavily dependent on the price of gold. Falling gold prices, combined with a lower production outlook, have compressed the company’s share price this year.

The question now is, can they recover? Or is there more downside ahead?

Are the shares a buy, sell or hold now?

According to the experts, there is still plenty of potential for the ASX gold stock to recover over the next 12 months.

Market Index data shows that the majority of brokers have a buy rating on the Northern Star shares. The $27.74 target price implies a potential upside of around 37% at the time of writing.

On TradingView data, analysts are significantly more bullish. Out of 18 analysts, 11 have a buy or strong buy rating on the stock. Another five rate the gold shares as a hold, and two have a sell stance. 

The average $26.37 target price implies a potential 30% upside at the time of writing. But some think Northern Star shares could soar another 65% to $33.50 over the next 12 months.

Bell Potter is one of the more bullish brokers on Northern Star shares. It has a buy rating and $35 target price. It notes that while the guidance downgrades are disappointing, it still sees potential positives given the high capital and operating costs at some of the company’s sites.

Baker Young has a sell rating on the shares. He said that the miner has underperformed and that the team would seek alternative gold exposure.

The post Down 36%: Will Northern Star shares ever recover? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• Buy, hold, sell: Charter Hall, Northern Star, Cochlear shares
• 5 things to watch on the ASX 200 on Tuesday
• With the gold price up on Monday, are Northern Star shares a good buy now?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Ramsay Health Care Ltd (ASX: RHC) shares have climbed higher into the green on Thursday morning.

At the time of writing, the ASX healthcare shares are up around 1% and changing hands at $41.62 a piece.

Today’s increase comes off the back of a 3.5% price hike yesterday.

The latest share price increase means Ramsay Health Care shares have now recovered around 15% from a dip in early June, and are around 20% higher for the year to date. Over the past year, the shares have risen 17%.

What happened to Ramsay Health Care shares?

Ramsay Health Care is one of the largest private healthcare providers in the world, with around 500 facilities across 11 countries. Its operations cover Australia, Europe, the UK, and Asia. 

The company faced several headwinds in 2025, including depressed earnings, market volatility, and ongoing cost pressures.

The ASX healthcare sector overall was under immense pressure throughout late 2025 and into early 2026 as macroeconomic pressures, rising inflation, higher cost of living, and regulatory uncertainty have driven a sector-wide share price downturn.

Why are the ASX healthcare shares now rebounding?

There hasn’t been any price sensitive news out of Ramsay Health Care shares to explain the share price turnaround in June.

It’s likely the result of an overall ASX healthcare sector recovery as investors rotated back into heavily-discounted healthcare names, and improved sentiment following the company’s latest earnings results.

The recovery has also been supported by a turnaround in the company’s finances. Ramsay Health Care posted its first-half FY26 results in February, where it confirmed underlying EBIT had grown 7.3%, underlying NPAT was up 8.1%, and its Australian hospital revenue was 8.2% higher. The company’s shares spiked over 10% on the day of the result.

The stronger half-year result seems to have helped investor sentiment shift from concerns about cost pressures and volatility towards a recovery story.

To me it looks like investors are still snapping up the shares while they’re trading for cheap.

Can Ramsay Health Care shares keep climbing higher? Here’s what the experts think

Analysts and brokers are divided about the outlook for Ramsay Health Care shares over the next 12 months.

Market Index data shows brokers are split between a buy and a sell rating. The average $40.60 target price, however, implies a potential 3% downside at the time of writing.

On TradingView data, sentiment is also split. Out of 12 analysts, seven have a hold rating on the healthcare stock. Another four rate the shares as a buy or strong buy and one has a strong sell stance.

The average $41.30 target price implies a downside of around 1% at the time of writing. But some expect the shares to jump 13% higher to $47.17, and others tip the stock to crash 20% back down to $32.90 a piece.

The post Ramsay Health Care shares rebound 15% in June: Can they keep going? appeared first on The Motley Fool Australia.

More reading

• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Judo Capital Holdings Ltd (ASX: JDO) shares are on the slide on Thursday.

In morning trade, the ASX 200 bank stock is down a massive 46% to 82 cents.

Why is this ASX 200 bank stock crashing?

Investors have been selling the small business lender’s shares after it released an update on expectations in FY 2026.

One item which appears to have caught the eye of investors is its FY 2026 cost of risk, which is now expected to be in the range of $116 million to $122 million.

Management advised that this reflects an increase in specific provisions primarily driven by three exposures across different sectors that have recently emerged, as a result of customer-specific developments.

Judo Capital now expects 90-days-past-due (90DPD+) and impaired loans to be approximately 3% of gross loans and advances (GLA) at 30 June.

One positive is that collective provision coverage at 30 June is expected to remain broadly in line with its third-quarter trading update, which was 94bps of GLA or 1.09% of standardised credit risk weighted assets.

It notes that provisioning levels include a management overlay for sectors impacted by the uncertain macroeconomic environment.

Profit guidance

In light of the above, the ASX 200 bank stock revealed that its profit before tax in FY 2026 is now expected to be between $163 million and $169 million or approximately 30% growth on FY 2025.

This is down meaningfully on its previous guidance of between $180 million and $190 million.

Looking to FY 2027, management has provided profit before tax guidance of between $210 million and $220 million. This represents growth of 30% again and takes into account the uncertain macroeconomic and geopolitical environment.

Commenting on the news, the ASX 200 bank stock’s CEO, Chris Bayliss, said:

We continue to see strong underlying momentum in the business. Recent credit outcomes have been driven by a small number of customers, who we are actively working with. These exposures have deteriorated subsequent to the customer-by-customer review undertaken in the third quarter and reflect recent, borrower-specific developments.

While today’s update is partly a result of the macro environment, it is nevertheless disappointing. Regardless, we remain confident in the strength of our underlying business and the quality of the portfolio. We have a proven customer value proposition, are profitable and well capitalised, and have a clear path to achieving a return on equity in the low-to-mid teens.

The post Which ASX 200 bank stock is crashing 46% on profit guidance downgrade? appeared first on The Motley Fool Australia.

More reading

• RBA keeps cash rate at 4.35% – What does it mean for investors?
• Broker names 3 ASX shares to buy now
• 6 ASX shares with 35% to 75% growth ahead of them: experts
• 3 oversold ASX shares to target right now for 70% gains
• Broker names 3 ASX All Ords shares to buy

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Ventia Services Group Ltd (ASX: VNT) shares are climbing on Thursday after the company announced a leadership change at the top.

At the time of writing, the Ventia share price is up 0.89% to $6.75.

The stock is now trading close to record highs, with Ventia shares up around 13% since the start of 2026 and 34% higher than this time last year.

Here’s what the company told the market today.

Ventia names its next CEO

According to the release, Ventia has appointed Mark Ralston as its next Managing Director and Group Chief Executive Officer.

Ralston will replace current Managing Director and Group CEO Dean Banks, with the change to take effect on 1 September 2026.

The company said the appointment follows a detailed internal and external succession process.

Ralston is already well known inside the business, having spent 12 years at Ventia. Over that time, he has held senior roles across enterprise strategy, mergers and acquisitions, telecommunications, and more recently defence and social infrastructure.

Ventia said Ralston will work closely with Banks over the coming months to support a smooth handover.

Chairman David Moffatt said Ralston has a deep understanding of Ventia’s business, customers and markets, and has made a strong contribution to the company’s performance and strategy.

Ralston said he was honoured to lead Ventia and pointed to the company’s “strong business, clear strategy and talented team”.

What does Ventia actually do?

Ventia provides infrastructure services across Australia and New Zealand.

Its work covers areas such as defence, water, power, gas, transport, telecommunications, resources and social infrastructure.

That includes maintaining defence bases, looking after roads and transport networks, supporting utilities, managing facilities, and providing services for government and large corporate customers.

Importantly, this gives Ventia a broad contract base across parts of the economy where maintenance and service work doesn’t just disappear when market conditions get tougher.

The business also has plenty of scale, with more than 35,000 employees and subcontractors working across more than 400 sites.

Keeping things steady

Leadership changes can sometimes make investors nervous, especially when a long-serving CEO is moving on.

But today’s share price reaction suggests the market is comfortable with the choice.

That is likely because Ralston is already well known inside the business. He has been involved with Ventia for more than a decade and has held roles across several parts of the group.

And the company’s recent share price performance also helps. Ventia has had a strong year, and the market appears comfortable with the stock moving into its next leadership phase.

The post Near record highs: Why this ASX 300 stock is rising today appeared first on The Motley Fool Australia.

More reading

• Ventia Services appoints new CEO in leadership succession
• Here are the top 10 ASX 200 shares today
• Why 4DMedical, IperionX, Pro Medicus, and Ventia shaares are storming higher today
• Ventia secures $133m contract extension at Australian Marine Complex

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

A2 Milk Company Ltd (ASX: A2M) shares are in the spotlight on Thursday.

In morning trade, the infant formula company’s shares are up 6% to $7.29.

This compares favourably to the performance of the S&P/ASX 200 Index (ASX: XJO), which is down 0.45% at the time of writing.

A2 Milk shares jump on big news

The catalyst for today’s gain has been the announcement of a special dividend.

According to the release, following the receipt of approval from the State Administration for Market Regulation (SAMR) to transition its two China label infant milk formula product registrations acquired in connection with the a2 Pokeno facility to a2 branded products, the board has decided to return a substantial amount of cash to shareholders.

A2 Milk advised that the board has now declared a NZ$300 million (A$245 million) special dividend that will be both fully franked and unimputed.

The company notes that this will be paid to eligible shareholders on 24 July 2026.

Speaking of eligibility, A2 Milk shares will go ex-dividend for this payout on 8 July. This means that investors need to own the company’s shares before the market close the day before to qualify for it.

The company estimates that the dividend has a value of 41.36 New Zealand cents per share (33.9 Australian cents per share). Based on its last close price of $6.85, this represented a dividend yield of just under 5%.

Commenting on the return, A2 Milk’s chair, Pip Greenwood, said:

With the necessary China regulatory approvals now in place, the Board is pleased to declare a $300 million special dividend. This reflects our commitment to delivering shareholder returns while maintaining disciplined capital management.

Should you invest?

While Bell Potter has yet to respond to this news, earlier this week it put a hold rating on A2 Milk shares with a price target of $6.90.

The broker commented:

This announcement is a positive development with regard to the internalisation of the CL supply chain and growth levers for FY27-29e. The debate at present is more nuanced around the wide FY27e consensus forecast ranges at EBITDA at NZ$296- 415m and NPAT at NZ$189-285m (both consistent on Bloomberg & VA) which is exceptionally wide for a ASX100 consumer stock.

This likely reflects the issues around 2H26e margin, the recent downgrade saw the top end of revenue consistent with the previous range but margin guidance reduced ~300bp in 2H26e, and expectations of additional marketing support in 1H27e. At current share price levels the stock sits at the more expensive side of the consumer sector (on a FY25-28e PEG ratio) and is likely to be materially more volatile given the polarising views on earnings expectations into the August guidance statement. Our forecasts largely split the divide and for this reason our Hold rating is unchanged.

The post A2 Milk shares jump amid $300 million special dividend appeared first on The Motley Fool Australia.

More reading

• A2 Milk declares $300 million special dividend after securing China approval
• Why A2 Milk, Calix, CSL, and Ioneer shares are charging higher today
• 5 things to watch on the ASX 200 on Tuesday
• Why A2 Milk, Lindian Resources, Perenti, and SGH shares are pushing higher today
• A2 Milk shares jump 7% on big China and special dividend news

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares are having another strong session on Thursday as investors continue to buy back into the ASX healthcare stock.

At the time of writing, the Pro Medicus share price is up 2.05% to $182.66.

It has been a big month for the company’s shares, which have now climbed around 40% over that period.

That bounce has helped repair some of the damage from earlier in the year. Even after the recent rally, Pro Medicus shares are still down roughly 17% since the start of 2026.

The latest announcement appears to have given the rally another push.

Pro Medicus signs AI agreement

According to the release, Pro Medicus has signed binding heads of agreement (HoA) with Echo IQ Ltd (ASX: EIQ).

The deal would see Pro Medicus take a stake in Echo IQ and work with the company to sell its products in the US.

Echo IQ is an AI and medical technology company working in cardiology. Its software is designed to help doctors make decisions using heart imaging data.

Under the agreement, Pro Medicus will make an initial $10 million investment in Echo IQ through secured convertible notes.

There is also room for another $10 million investment if Echo IQ receives US Food and Drug Administration clearance for its EchoSolv HF product.

EchoSolv HF is an AI-powered tool that helps identify heart failure risk using cardiac imaging data.

Furthermore, the agreement includes a proposed reseller arrangement. This allows Pro Medicus to market and distribute Echo IQ’s products to its healthcare customers, particularly in the United States.

Echo IQ deal opens another door

The update seems to have gone down well because it gives Pro Medicus another way to build out its cardiology offering.

The company is already best known for its Visage Imaging platform, which is used by large healthcare groups to view and manage medical images.

This agreement could add Echo IQ’s AI technology to the mix, while giving Echo IQ access to a much larger customer network.

Pro Medicus CEO Dr Sam Hupert said the company is “looking to offer Visage 7 Cardiology customers the option of using Echo IQ’s technology.”

He said the agreement fits with the company’s strategy of offering a carefully selected suite of algorithms. That includes its own technology, tools created with clinical partners, and third-party algorithms such as Echo IQ.

What comes next?

It’s worth remembering that despite the positive news, the agreement still needs final legal documentation.

The companies said the deal is expected to be finalised in the coming weeks.

Echo IQ also said its FDA submission for EchoSolv HF remains on track for an outcome in the near-term.

The post Pro Medicus shares jump again as AI deal adds fuel to 40% rally appeared first on The Motley Fool Australia.

More reading

• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• 2 ASX 200 shares I’d buy for powerful growth
• 3 buy-rated ASX tech shares with bright futures
• US chip stocks were smashed overnight. So why are ASX tech shares rising?
• 5 ASX growth shares I want in my portfolio in FY27

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Lendlease Group (ASX: LLC) share price is in focus today after a trading pause was announced by the ASX, pending further updates from the company.

What did Lendlease Group report?

• Trading in Lendlease securities has been temporarily paused by the ASX.
• No financial metrics or earnings details have been disclosed at this time.
• Investors await a further announcement regarding the reason for the trading halt.

What else do investors need to know?

The ASX has temporarily paused trading of Lendlease Group shares as it awaits additional information from the company. This is a standard procedure when the market is expecting material news that could affect the share price.

It’s not uncommon for companies to request a trading halt ahead of significant announcements, which might range from financial results, capital raisings, acquisitions, or other strategic updates. Lendlease has not provided specific details yet.

What’s next for Lendlease Group?

All eyes are on Lendlease for its next announcement, which should clarify the reason for the trading pause. Investors will be looking for more information before making any decisions.

The company’s future direction will become clearer once further details are released to the market.

Lendlease Group share price snapshot

Over the past 12 months, Lendlease shares have declined 47%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Lendlease Group shares paused pending further announcement appeared first on The Motley Fool Australia.

More reading

• Corporate Travel Management updates investors on delayed FY25 results and UK remediation
• Worley flags FY26 earnings hit from Middle East delays and currency impact
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Corporate Travel Management Ltd (ASX: CTD) share price is in focus after the company released an update highlighting delays to its FY25 and 1HFY26 financial statements and progress on UK customer remediation.

What did Corporate Travel Management report?

• FY25 and 1HFY26 financial statements are substantially advanced but still incomplete
• FY25 and 1HFY26 accounts now expected to be lodged in August 2026
• Estimated FY24 revenue restatement of $10–15 million in the ANZ region, mostly relating to prior years
• Impairment of Europe goodwill expected at GBP 92 million
• Further goodwill impairment expected in ANZ (AUD 77 million) and North America (USD 49 million)

What else do investors need to know?

Corporate Travel Management is focused on completing three key, interconnected activities: finalising financing to support UK remediation, executing agreements with affected UK customers, and completing outstanding financial reporting and audit procedures.

The UK remediation process is well advanced, with Corporate Travel Management in the final stages of negotiating staged refund arrangements with key customers. This remains subject to completion of the FY25 accounts and associated financing, with lenders engaged regarding these developments.

What did Corporate Travel Management management say?

Acting Group CEO Ana Pedersen said:

We recognise the delay is deeply frustrating for shareholders and acknowledge the uncertainty it has created.

We have made meaningful progress towards finalising CTM’s financial statements, UK customer remediation and financing workstreams.
As we move through the final stages, the remaining tasks are interdependent, and we are working through them carefully and with rigour, to ensure a thorough and appropriate outcome.

Importantly, the underlying business remains resilient, with strong customer retention and consistent quality service across our global operations.

What’s next for Corporate Travel Management?

The company now aims to complete and lodge its FY25 and 1HFY26 financial statements in August. Finalising agreements with lenders and impacted UK customers remains a top priority, alongside implementing the staged remediation refunds.

Management says the underlying operations continue to display resilience, and the company will provide further market updates as soon as the remaining processes are finalised.

View Original Announcement

The post Corporate Travel Management updates investors on delayed FY25 results and UK remediation appeared first on The Motley Fool Australia.

More reading

• Lendlease Group shares paused pending further announcement
• Worley flags FY26 earnings hit from Middle East delays and currency impact
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has positions in and has recommended Corporate Travel Management. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.